Condition: Rare Cancers · Cholangiocarcinoma · Cancer of Unknown Primary Site · Sponsor: TargetCancer Foundation
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
This description comes directly from the study's public registry record.
Mary Oster · 617-299-0389 · track@targetcancer.org
Always discuss trial participation with your own doctor first.
| TargetCancer Foundation | Cambridge, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504604